BMS Scoops Cormorant In $520M Immuno-Oncology Deal

 
• By Mike Ward
  
Maarten de Château
Maarten de Château, CEO of Cormorant Pharmaceuticals • Source: Cormorant Pharmaceuticals AB

More from Business

More from Scrip